FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Tes

GRAIL Inc.

(NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S.

Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.

The Medical Devices Advisory Committee has officially scheduled a meeting for September 23.

During this session, the panel will thoroughly review the Premarket Approval (PMA) application for the Galleri multi-cancer early detection (MCED) blood test.